Digoxin and mortality: lessons for observational studies
Editors' Report for 2015, December 2015
Issue Highlights
Classifying ADRs – does dose matter?
Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis
Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?
Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis
The mass action equation in pharmacology
Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology
The law of mass action and the pharmacological concentration–effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions
Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics
Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?
Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients
A pharmacokinetic–pharmacodynamic model for intrathecal baclofen in patients with severe spasticity
Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer
Alkali replacement raises urinary citrate excretion in patients with topiramate-induced hypocitraturia
Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds
Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study
Olaparib
rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis
Reviewers' List 2015